University of Oxford
Continue with FacebookLooking to list your PhD opportunities? Log in here.
We have 65 University of Oxford Biological Sciences PhD Projects, Programmes & Scholarships
University of Oxford Biological Sciences PhD Projects, Programmes & Scholarships
We have 65 University of Oxford Biological Sciences PhD Projects, Programmes & Scholarships
PhD saved successfully
DPhil in Paediatrics and MSc (by Research) in Paediatrics
The Department of Paediatrics is a world leader in child health research. Our work spans from early proof-of concept fundamental science all the way up to its application in clinical settings. Read more
Development of bioactive ultrasound-responsive coatings for the prevention and treatment of orthopaedic implant-related infections
Commercial partner: Adler Ortho®. Implant-related orthopaedic infections pose a very significant burden on patients and healthcare systems globally. Read more
Developing translatable TetraVecta-enabled allogeneic regulatory T cell therapy
Commercial partner: Oxford Biomedica (UK) Ltd (OXB). Pathological immune activation is a hallmark of several diseases from autoimmunity to solid organ transplant rejection. Read more
High-throughput characterisation of the functional antibody epitope landscape of surface protein targets to guide vaccine and biologic design
Commercial partner: DJS Antibodies. Understanding the nature of antibody-antigen interactions and how these relate to functional outcomes is vital in guiding the rational design of next-generation vaccines and monoclonal antibody (mAb) therapeutics. Read more
Understanding the molecular reach of therapeutic CD3-targeting bi-specific antibodies to optimise efficacy
Commercial partner: GSK. Antibodies are soluble proteins that contribute to immune responses by directly targeting pathogens. Read more
An integrative mathematical approach to understand how intraplaque angiogenesis and vascular structure impact atherosclerosis and their potential as novel therapeutic targets
Commercial partner: Novo Nordisk. Atherosclerosis is a disease of large and medium-sized arteries that is complicated by cardiovascular events, such as myocardial infarction and stroke, which are typically driven by arterial thrombosis. Read more
Target enrichment of transposable elements for direct RNA sequencing
Commercial partner: Oxford Nanopore Technologies. Background. In our conventional understanding, we often assume that all cells in our body possess the same genetic information. Read more
Technological Advancements In Radiotherapy Leading To Dose Delivery via FLASH
Commercial partner: Teledyne e2v (Teledyne UK Limited). Over 25% of cancer patients in the UK receive radiotherapy, often delivered in multiple fractions over several weeks. Read more
Ageing Beyond Earth - New drug targets
Commercial partner: Metavisionaries and Space Application Services (MSA). Population ageing is a transformative social phenomenon impacting sectors like labor force and finances. Read more
Unravelling the effects of mitochondrial replacement therapy on mtDNA transmission
Commercial partner: Juno Genetics. Normal oocytes contain ~100,000 copies of mtDNA, which are effectively identical. Patients with mtDNA disease may harbour both mutant and normal mtDNA (heteroplasmy). Read more
Cross-tissue and cross-disease immunometabolic landscape characterisation at single-cell resolution
Commercial partner: Janssen Biotech, Inc. Immune cells play a fundamental role in health and disease, with many of their functions relying on the careful orchestration of metabolic and energetic pathways. Read more
Imaging-based analysis of signalling pathways triggered by immune checkpoint receptors
Commercial partner: Gilead Sciences (Oxford). Read more
A Novel K+ Channel Target (KCNK13/THIK1) for Neurodegenerative Disorders: Understanding its mechanism of inhibition by small molecule drugs and biological therapeutics
Commercial partner: Cerevance. The student will be involved in an exciting multidisciplinary project aimed at determining the structural and molecular mechanisms of a range of novel inhibitors of the THIK1 K2P K+ channel. Read more
Development of a semi-automated CT-brain analysis tool for application to real world clinical cohorts
Commercial partner: Brainomix, Oxford. Background. CT-brain imaging is the standard brain imaging modality used in the NHS and globally and is cheaper and better tolerated than MRI particularly in older, frail, multimorbid patients in whom MRI may be contraindicated. Read more